A comprehensive view of Phase 3 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GSK updates prescribing information for the ovarian cancer drug Zejula, limiting use to second-line maintenance therapy only to patients with certain mutation types; change was made at the request of FDA following review of Phase 3 clinical results
Published: November 14, 2022 by PharmaBiz (India)
GlaxoSmithKline's Blenrep to treat multiple myeloma fails to achieve primary endpoint in Phase 3 confirmatory trial
Published: November 08, 2022 by Fitch Solutions Sector Intelligence
FDA accepts for priority review Gilead's sBLA for Trodelvy injectable for pre-treated HR+/HER2- metastatic breast cancer; sBLA based on Phase 3 data, which met its primary endpoint for progression-free survival
Published: October 13, 2022 by ENP Newswire
GSK hits back in high-stakes RSV vaccine game, posting phase 3 data that suggest it has edge on Pfizer
Published: October 13, 2022 by FierceBiotech
Sanofi partners with TrialSpark to pursue acquisition/in-licensing and development of clinical-stage Phase 2, Phase 3 drug candidates in areas of high unmet patient need; firms are jointly targeting six transactions over the next three years
Published: October 04, 2022 by PR Newswire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count